Chonnam National University Medical School Researchers Describe Research in Lupus Nephritis (Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis)

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily-Investigators publish new report on lupus nephritis. According to news reporting from Chonnam National University Medical School by NewsRx journalists, research stated, "Recently, we developed hydrophobically modified glycol chitosan (HGC) nanomicelles loaded with tacrolimus (TAC) (HGC-TAC) for the targeted renal delivery of TAC. Herein, we determined whether the administration of the HGC-TAC nanomicelles decreases kidney injury in a model of lupus nephritis." Our news editors obtained a quote from the research from Chonnam National University Medical School: "Lupus-prone female MRL/lpr mice were randomly assigned into three groups that received intravenous administration of either vehicle control, an equivalent dose of TAC, or HGC-TAC (0.5 mg/kg TAC) weekly for 8 weeks. Age-matched MRL/MpJ mice without Fas Ipr mutation were also treated with HGC vehicle and used as healthy controls. Weekly intravenous treatment with HGC-TAC significantly reduced genetically attributable lupus activity in lupus nephritis-positive mice. In addition, HGC-TAC treatment mitigated renal dysfunction, proteinuria, and histological injury, including glomerular proliferative lesions and tubu-lointerstitial infiltration. Furthermore, HGC-TAC treatment reduced renal inflammation and inflammatory gene expression and ameliorated increased apoptosis and glomerular fibrosis.